Clinical Trial Results:
Uncontrolled, multicenter, dose finding, safety and pharmacokinetic study of AVE1642, an anti-Insulin-like Growth Factor-1 Receptor (IGF-1R/ CD221) monoclonal antibody, administered as single agent and in combination with anticancer therapies in patients with advanced solid tumors
Summary
|
|
EudraCT number |
2006-005978-51 |
Trial protocol |
GB |
Global completion date |
15 Oct 2010
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
02 Mar 2016
|
First version publication date |
02 Mar 2016
|
Other versions |
|
Summary report(s) |
TED6421 |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.